These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21713517)

  • 1. Clinical impact of fluvoxamine-mediated long QTU syndrome.
    Nia AM; Dahlem KM; Gassanov N; Hungerbühler H; Fuhr U; Er F
    Eur J Clin Pharmacol; 2012 Jan; 68(1):109-11. PubMed ID: 21713517
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-induced long QT syndrome: a continuing challenge in the field.
    Glatter KA; Hamdan MH; Zhang Q; Chiamvimonvat N
    J Cardiovasc Electrophysiol; 2007 Jul; 18(7):696-7. PubMed ID: 17537200
    [No Abstract]   [Full Text] [Related]  

  • 3. Observation of QTc prolongation in an adolescent girl during fluvoxamine pharmacotherapy.
    Brzozowska A; Werner B
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):591-2. PubMed ID: 19877986
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluvoxamine for the treatment of anxiety disorders in children and adolescents.
    Isaacs E
    N Engl J Med; 2001 Aug; 345(6):466-7. PubMed ID: 11496864
    [No Abstract]   [Full Text] [Related]  

  • 5. Quetiapine and the need for a thorough QT/QTc study.
    Hasnain M; Vieweg WV; Howland RH; Kogut C; Breden Crouse EL; Koneru JN; Hancox JC; Digby GC; Baranchuk A; Deshmukh A; Pandurangi AK
    J Clin Psychopharmacol; 2014 Feb; 34(1):3-6. PubMed ID: 24346758
    [No Abstract]   [Full Text] [Related]  

  • 6. Extended-release fluvoxamine (Luvox CR).
    Med Lett Drugs Ther; 2008 Jun; 50(1289):50-1. PubMed ID: 18583947
    [No Abstract]   [Full Text] [Related]  

  • 7. Ecchymoses as an adverse effect of fluvoxamine treatment in an adolescent girl.
    Vlatka BM; Branka AM; Branimir M
    Gen Hosp Psychiatry; 2010; 32(4):e9-e10. PubMed ID: 20633737
    [No Abstract]   [Full Text] [Related]  

  • 8. Photosensitivity reaction associated with selective serotonin re-uptake inhibitors: possible cross-sensitivity?
    Cheng YC; Huang MC
    Psychiatry Clin Neurosci; 2014 Mar; 68(3):244. PubMed ID: 24895743
    [No Abstract]   [Full Text] [Related]  

  • 9. Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder.
    Harris E; Eng HY; Kowatch R; Delgado SV; Saldaña SN
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):347-53. PubMed ID: 20807074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine approved for treating OCD in children.
    J Psychosoc Nurs Ment Health Serv; 2001 Jan; 39(1):11. PubMed ID: 11197991
    [No Abstract]   [Full Text] [Related]  

  • 11. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.
    Pratheesh PJ; Praharaj SK; Srivastava A
    Psychopharmacol Bull; 2011; 44(1):70-3. PubMed ID: 22506441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine-induced intracranial hypertension in a 10-year-old boy.
    Samant H; Samant P
    Indian J Ophthalmol; 2018 May; 66(5):712-714. PubMed ID: 29676327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant-induced hypomania in obsessive-compulsive disorder.
    Rihmer Z; Barsi J; Belsõ N; Pestality P; György S
    Int Clin Psychopharmacol; 1996 Sep; 11(3):203-5. PubMed ID: 8923100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
    Andrade C
    J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder.
    Nair NP; Bakish D; Saxena B; Amin M; Schwartz G; West TE
    Anxiety; 1996; 2(4):192-8. PubMed ID: 9160622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.